NCT04267965

Brief Summary

In this study, investigators measure patient's voice frequency, swallowing function, and O2 desaturation of the 6 mins walking test before surgery and 4 months after surgery, to find the increase of voice frequency, and swallowing function and the decrease of O2 desaturation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2017

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2019

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

January 22, 2020

Completed
22 days until next milestone

First Posted

Study publicly available on registry

February 13, 2020

Completed
Last Updated

February 13, 2020

Status Verified

February 1, 2020

Enrollment Period

2 years

First QC Date

January 22, 2020

Last Update Submit

February 11, 2020

Conditions

Keywords

Voice impairmentairway invasionrespiratory function

Outcome Measures

Primary Outcomes (9)

  • Successful surgery is defined as iPTH levels less than 72 pg/dL within one week after surgery

    After successful surgery, patients were recruited in the study, and we excluded patients with a surgical failure.

    one week after surgery

  • Voice impairment(GRBAS)

    speech impairment and speech quality were evaluated with GRBAS on a scale (0-3), VHI-10 (\>11, abnormal) and (EAT-10) (≥ 3, abnormal) . \*GRBAS (grade, roughness, breathiness, asthenia, strain) scale grades hoarseness, roughness, breathiness, aesthenia (weakness), and strain on a scale of 0-3 0 = normal, 1 = mild degree, 2 = moderate degree, and 3 = high degree

    4 months after surgery

  • Voice impairment(VH1-10)

    speech impairment and speech quality were evaluated with voice handicap index (VHI-10) (\>11, abnormal) 0-4 Rating Scale 0 = Normal 1. = Almost Normal 2. = Sometimes 3. = Abnormal 4. = Always

    4 months after surgery

  • Voice impairment(EAT-10)

    speech impairment and speech quality were evaluated with EAT-10 (≥ 3, abnormal) . \*eating assessment tool (EAT-10) 0 - 4 Rating Scale 0 = No problem 1. = Mild Problem 2. = Mild to moderate 3. = Moderate problem 4. = Severe problem

    4 months after surgery

  • Acoustic voice analysis

    mean frequency (F0, Hz); Noise-to-Harmonic Ratio (NHR), jitter(%), and shimmer (%)

    4 months after surgery

  • Vocal cord examination

    The maximal phonation time (sec) and s/z ratio were measured with circumferentially vented pneumotachography mask and differential transducers of the Aerophone system .

    4 months later

  • Fiber optic endoscopic evaluation of swallowing (FEES)

    Vocal cord mobility, vocal cord closure (complete or incomplete), airway invasion during swallowing were inspected with fiber-optic endoscopy to show premature spillage, penetration-aspiration scale levels . The Yale pharyngeal residue severity rating scale for vallecula and pyriform sinus (0-4) (non-trace-mild-moderate-severe) and pyriform sinus (0-4) were also performed.

    4 months later.

  • Pulmonary function test

    Forced vital capacity (FVC) (L), forced expiratory volume in 1 second (FEV1), bronchodilator test (BDT) (a positive response to BDT defined by the American Thoracic Society as an increase in FEV1 or FVC ≥ 12% and 200 ml), total lung capacity (TLC) (L), and alveolar volume (VA) using MasterScope (Jaeger, VIASYS healthcare GmbH, Höchberg, Germany), and diffusion capacity of the lung for carbon monoxide (DLCO) (%) using Vmax Autobox (SensorMedics, a subsidiary of VIASYS healthcare, California, USA).

    4 months later

  • 6MWT were performed.

    The 6 minutes walking test (6MWT) was also performed to evaluate distance (meter) and O2 desaturation (differences of O2 saturation between pre- and post-tests) (defined as positive if O2 desaturation ≧ 4%).

    4 months later

Study Arms (2)

Group A

Patients who have been successfully operated on with total parathyroidectomy for symptomatic secondary hyperparathyroidism and their PTH levels are below 72 pg/dL within one week after surgery.

Procedure: parathyroidectomy plus bilateral thymectomy and autotransplantation

Group B

Patients who have had regular dialysis and their iPTH levels are around 500 pg/dL

Interventions

Patients should receive total parathyroidectomy plus bilateral thymectomy and autotransplantation

Group A

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

We included patients who had symptomatic secondary hyperparathyroidism and were successfully operated during the two years period (Aug 1 2017 - July 31 2019).

You may qualify if:

  • age over 20 years
  • chronic renal failure with regular dialysis
  • iPTH\> 800pg/mL, Ca \> 10.1 mg/dL, and P \> 5.5 mg/dL
  • symptoms of bone pain, skin itching, general weakness, insomnia and osteoporosis (T score\< -2.5)

You may not qualify if:

  • pregnancy women
  • patients after kidney transplantation
  • a failure in surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fong-Fu Chou

Kaohsiung City, 833, Taiwan

Location

Related Publications (10)

  • Okada M, Tominaga Y, Yamamoto T, Hiramitsu T, Narumi S, Watarai Y. Location Frequency of Missed Parathyroid Glands After Parathyroidectomy in Patients with Persistent or Recurrent Secondary Hyperparathyroidism. World J Surg. 2016 Mar;40(3):595-9. doi: 10.1007/s00268-015-3312-1.

  • Wood JM, Athanasiadis T, Allen J. Laryngitis. BMJ. 2014 Oct 9;349:g5827. doi: 10.1136/bmj.g5827. No abstract available.

  • Arffa RE, Krishna P, Gartner-Schmidt J, Rosen CA. Normative values for the Voice Handicap Index-10. J Voice. 2012 Jul;26(4):462-5. doi: 10.1016/j.jvoice.2011.04.006. Epub 2011 Aug 4.

  • Belafsky PC, Mouadeb DA, Rees CJ, Pryor JC, Postma GN, Allen J, Leonard RJ. Validity and reliability of the Eating Assessment Tool (EAT-10). Ann Otol Rhinol Laryngol. 2008 Dec;117(12):919-24. doi: 10.1177/000348940811701210.

  • Eckel FC, Boone DR. The S/Z ratio as an indicator of laryngeal pathology. J Speech Hear Disord. 1981 May;46(2):147-9. doi: 10.1044/jshd.4602.147.

  • Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetration-aspiration scale. Dysphagia. 1996 Spring;11(2):93-8. doi: 10.1007/BF00417897.

  • Neubauer PD, Rademaker AW, Leder SB. The Yale Pharyngeal Residue Severity Rating Scale: An Anatomically Defined and Image-Based Tool. Dysphagia. 2015 Oct;30(5):521-8. doi: 10.1007/s00455-015-9631-4. Epub 2015 Jun 7.

  • Richter DC, Joubert JR, Nell H, Schuurmans MM, Irusen EM. Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2008;3(4):693-9. doi: 10.2147/copd.s948.

  • Single breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique. Statement of the American Thoracic Society. Am Rev Respir Dis. 1987 Nov;136(5):1299-307. doi: 10.1164/ajrccm/136.5.1299. No abstract available.

  • Waatevik M, Johannessen A, Gomez Real F, Aanerud M, Hardie JA, Bakke PS, Lind Eagan TM. Oxygen desaturation in 6-min walk test is a risk factor for adverse outcomes in COPD. Eur Respir J. 2016 Jul;48(1):82-91. doi: 10.1183/13993003.00975-2015. Epub 2016 Apr 13.

MeSH Terms

Conditions

DysphoniaRespiratory Aspiration

Interventions

ParathyroidectomyTransplantation, Autologous

Condition Hierarchy (Ancestors)

Voice DisordersLaryngeal DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsRespiration DisordersPathologic Processes

Intervention Hierarchy (Ancestors)

Endocrine Surgical ProceduresSurgical Procedures, OperativeTransplantation

Study Officials

  • Chang Huang-Chih, MD

    Co-host

    STUDY DIRECTOR
  • Chen Jib-Bor, MD

    Co-host

    STUDY DIRECTOR
  • Lai Chi-Chih, MD

    Co-host

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
4 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant professor

Study Record Dates

First Submitted

January 22, 2020

First Posted

February 13, 2020

Study Start

August 1, 2017

Primary Completion

July 31, 2019

Study Completion

July 31, 2019

Last Updated

February 13, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations